Risk-factor analysis for predicting progressive- or quiescent-type chronic graft-versus-host disease in a patient cohort with a history of acute graft-versus-host disease after allogeneic stem cell transplantation

Bone Marrow Transplantation
S K SohnI-H Shin

Abstract

This study attempts to identify variables that can predict the development of progressive- or quiescent-type chronic GVHD (pq cGVHD) and transplant outcomes after the diagnosis of cGVHD in 99 patients who experienced acute GVHD (aGVHD) after allogeneic SCT. The prognostic significance of various clinical parameters at diagnosis of cGVHD was examined to determine the prognostic factors for GVHD-specific survival (GSS) in patients with pq cGVHD. Among 118 patients who experienced any degree of aGVHD, 99 were evaluated for cGVHD. The incidence of overall and extensive pq cGVHD at 2 years was estimated as 84.4 and 63.1%, respectively. A multivariate analysis showed that severe aGVHD (grade 3, 4) (P=0.022), primary treatment failure (P=0.009) and elevated alkaline phosphatase (P=0.001) were all significant independent factors predicting a higher overall incidence of pq cGVHD. The GSS and probability of systemic immunosuppressive treatment at 2 years after diagnosis of cGVHD were estimated as 55.9 and 51.9%. GVHD-specific survival was significantly associated with performance status (P=0.004) and lymphocytopenia (<or=1000/microl, P=0.022) at diagnosis of cGVHD by Cox's proportional hazard model. Severe aGVHD, primary treatment failur...Continue Reading

References

Feb 27, 2001·Blood·G B Vogelsang
Aug 18, 2001·Bone Marrow Transplantation·V RatanatharathornJ P Uberti
Jan 14, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Mats RembergerOlle Ringdén
Apr 30, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stephanie J LeeMary E D Flowers
Apr 3, 2004·British Journal of Haematology·Dong Hwan KimKyu Bo Lee
May 15, 2004·British Journal of Haematology·Meghan A Higman, Georgia B Vogelsang
Feb 11, 2005·Blood·Christian A WysockiJonathan S Serody

❮ Previous
Next ❯

Citations

Nov 10, 2009·Transplantation·Marie RobinGérard Socié
Jun 15, 2011·Expert Review of Hematology·Jacob Rozmus, Kirk R Schultz
Jul 1, 2017·The Journal of Clinical Investigation·Kelli Pa MacDonaldGeoffrey R Hill
Jun 22, 2021·Frontiers in Immunology·Andrzej LangeEmilia Jaskuła

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2021 Meta ULC. All rights reserved